Research and application of PD-1 / PD-L1 inhibitors in small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 695-698, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-823582
ABSTRACT
Small cell lung cancer (SCLC)is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently,the standard treatment for SCLC is still chemoradiotherapy,and although SCLC is sensitive to chemotherapy in the early stage,recurrence and metastasis often occur due to drug resis-tance. In recent years,immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1)and its ligand (PD-L1)inhibitors,such as nivolumab,atezolizumab and pabolizumab,have shown good antitumor activity in clinical studies of SCLC,and PD-1 / PD-L1 inhibitors com-bined with chemotherapy have shown better efficacy,providing a new strategy for the treatment of SCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS